Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenoma, Islet Cell × belzutifan × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

von Hippel-Lindau Disease 2 Pheochromocytoma 2 Paraganglioma 2 Carcinoma, Renal Cell 2 Neuroectodermal Tumors, Primitive 1 Neoplasm Metastasis 1 Kidney Neoplasms 1 Hemangioblastoma 1 Glioblastoma 1 Adenoma, Islet Cell 1

Interventions

pentetreotide 1 fludarabine phosphate 1 belzutifan 1 Specimen Handling 1 Magnetic Resonance Spectroscopy 1 LY2940680 1 Interleukin-13 1 Fluorodeoxyglucose F18 1 Cyclophosphamide 1 Biopsy 1 90Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04924075 2026-02-24

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡